An analysis reported by several outlets says a UK-US trade agreement on medicines could lead to large numbers of excess deaths in England by the mid-2030s. The figures cited include an estimate of about 229,000 excess deaths by 2036, alongside warnings that the NHS would face significant financial pressure if it must pay more for new medicines under the deal. The analysis, reported by The Guardian, argues the NHS would need to divert around £45 billion from other essential services to fund medicines covered by the agreement.
Campaigners and medical commentators quoted in coverage describe the arrangement as harmful to the health system and warn it could worsen outcomes for patients. Some reactions include concerns that the deal could damage both the NHS and the broader economy.
Government ministers dispute this interpretation, according to The Guardian, saying the agreement is intended to help British drug exports to the US avoid tariffs and to give patients access to treatments that might otherwise be unavailable. The overall reporting presents competing claims: one side focuses on funding diversion and projected mortality impacts, while the other emphasizes export access and patient treatment availability.
